Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.Jueming Chen, Yanna Zhang, Wei Wei et al.|Journal of Clinical Oncology|2021Cited by 2
Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II studyJueming Chen, Yanna Zhang, Jiaqi Qiu et al.|Gynecologic Oncology|2021Cited by 2
Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.Yanna Zhang, He Huang, Jueming Chen et al.|Journal of Clinical Oncology|2020Cited by 1